VIVUS, Inc. (VVUS) Earnings: An Early Look

Page 1 of 2

Earnings season is now starting to wind down, with most companies already having reported their quarterly results. But there are still some companies left to report, and VIVUS, Inc. (NASDAQ:VVUS) is about to release its quarterly earnings report. The key to making smart investment decisions with stocks releasing their quarterly reports is to anticipate how they’ll do before they announce results, leaving you fully prepared to respond quickly to whatever inevitable surprises arise. That way, you’ll be less likely to make an uninformed kneejerk reaction to news that turns out to be exactly the wrong move.

VIVUS, Inc. (NASDAQ:VVUS)VIVUS was fortunate enough to be the first company to bring a new anti-obesity drug to market, but Qsymia hasn’t been everything that investors had hoped it would be. Let’s take an early look at what’s been happening with VIVUS over the past quarter and what we’re likely to see in its quarterly report on Monday.

Stats on VIVUS

Analyst EPS Estimate ($0.44)
Year-Ago EPS ($0.14)
Revenue Estimate $3.34 million
Change From Year-Ago Revenue NM
Earnings Beats in Past 4 Quarters
0

Sources: Yahoo! Finance, S&P Capital IQ. NM = not meaningful; VIVUS had no revenue in the year-ago period.

Will VIVUS finally pay off for investors?
Analysts aren’t too optimistic about VIVUS coming into its report, as they’ve cut nearly a dime off earnings-per-share estimates for the quarter over the past few months, and for full-year 2013, current consensus has fallen by more than $0.25 per share over the same time frame. But investors haven’t been deterred by those concerns, as the stock is up more than 25% since mid-November.

VIVUS wasn’t the first company to get its obesity drug approved, as Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) managed to get its Belviq drug past the FDA gates first. But Arena hasn’t been able to release Belviq pending DEA classification, VIVUS got a head start on sales. After a slow start, sales have picked up somewhat, with the company saying that sales in the late November to late December period rose 68% from the prior four-week period.

More recently, though, questions have arisen about whether any blockbuster anti-obesity drug will emerge from the fray. Safety issues have again come up, with the regulatory agency responsible for approving drugs in the European Union rejecting VIVUS’s appeal pending more clinical data on potential risks of cardiovascular problems. Moreover, even if safety concerns with anti-obesity drugs get resolved successfully, most medications can’t solve obesity without accompanying changes in patient behavior.

Moreover, cost has been a concern, as 30% of patients have given up their prescriptions. Aetna Inc. (NYSE:AET) changed its policies to call Qsymia and Belviq “medically necessary” and therefore allowed them to qualify for drug benefits in many cases, and pharmacy benefits manager Express Scripts Holding Company (NASDAQ:ESRX) has added Qsymia to its national formulary, opening the door to copayments of $50 to $60 for many patients. Other insurance providers may conclude that encouraging obesity treatment leads to lower overall health costs in the long run and therefore make the same change.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 44 percentage points in 21 months Learn how!

Lists

The Top 10 States With Fastest Internet Speeds

10 Best Places to Visit in USA in August

Top 10 Cities to Visit Before You Die

Top 10 Genetically Modified Food In the US

15 Highest Grossing Movies Opening Weekend

5 Best Poker Books For Beginners

10 Strategies Hedge Funds Use to Make Huge Returns

Top 10 Fast Food Franchises to Buy

10 Best Places to Visit in Canada

Best Summer Jobs for Teachers

10 Youngest Hedge Fund Billionaires

Top 10 One Hit Wonders of the 90s

Fastest Growing Cities In America

Top 10 U.S. Cities for Freelancers

Top 9 Most Popular Free iPhone Apps

Top 10 Least Expensive Private Business Schools in the US

Top 15 Most Expensive Countries in the World – 2014

Top Businesses to Invest In

Top 5 Things You Might Be Doing Wrong With Your Business

Top 5 Strategic Technology Trends in 2014

Top Rags to Riches Stories

Parenting Behavior That Promotes Future Leaders

Top 5 Mistakes Made by Small Businesses

Top 5 Most Common and Potentially Devastating Financial Blunders

Top 5 Highest Paying Jobs for Web Designers

Top 6 Most Respected Professions that Also Pay Well

Top 5 Pitfalls Investors Should Avoid

Top 6 Lawyers and Policy Makers Under 30

Top 6 New Year’s Resolutions for Entrepreneurs

Top 7 Locations to Check in on Facebook

Top 5 Mistakes made by Rookie eBay Sellers

Top 7 eBook Publishers in 2013

Top 6 Health Industry Trends in 2014

5 Lessons for Entrepreneurs from Seth Godin

Top 5 Success Tips from Jordan Belfort – the Wolf of Wall Street

Best Master’s in Finance Degree Programs

Top 6 Earning Celebrities Over 50

The most expensive sports to play

Top 7 Earning Celebrities Under 25

Best 7 Online Courses to Take: Free Finance MOOCs

Top 6 Bad Habits that Promote Failure

20 Most Valuable Soccer Teams in the World in 2013

12 Most Expensive Countries for Foreign Students

Top 30 Most Influential Women in the World

Top 20 Most Expensive New Year Eve Shows

Top 5 Best Vocational Careers

Top 10 Jobs for 2014 by Salary Gain (Predictions)

Top 5 Digital Trends for 2014

Top 6 Things You Can Do To Increase Your Productivity

Top 9 Trending Smartphones in 2013

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!